Japan Antidiabetic Sulphonylureas Market was valued at USD 0.85 Billion in 2022 and is projected to reach USD 1.10 Billion by 2030, growing at a CAGR of 4.0% from 2024 to 2030.
The landscape of antidiabetic sulphonylureas in Japan has experienced notable shifts in recent years, reflecting evolving treatment paradigms and industry requirements. Historically, sulphonylureas played a central role in managing type 2 diabetes mellitus (T2DM) in Japan. However, data from 2002 to 2020 indicates a decline in both the prescription rates and dosages of these medications. This trend aligns with the introduction and increased adoption of alternative oral antidiabetic drugs, such as biguanides, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium–glucose cotransporter 2 (SGLT2) inhibitors. citeturn0search0
In 2023, the Japanese antidiabetics market generated approximately USD 2,698.7 million in revenue and is projected to reach USD 4,798.5 million by 2030, growing at a compound annual growth rate (CAGR) of 8.6%. Within this market, glucagon-like peptide-1 (GLP-1) receptor agonists emerged as the largest revenue-generating drug class in 2023 and are anticipated to be the fastest-growing segment during the forecast period. citeturn0search3
Despite the overall decline in sulphonylurea prescriptions, these agents remain integral in certain therapeutic scenarios. A cross-sectional survey involving 15,652 patients revealed that 35.4% of those treated by general practitioners and 29.2% by specialists were prescribed sulphonylureas. Notably, among patients on sulphonylurea monotherapy, 35.2% achieved HbA1c levels below 6.5%, while 14.0% had levels exceeding 8.0%. Patients with higher HbA1c levels tended to have a higher body mass index, were more frequently prescribed glibenclamide, and received higher sulphonylurea doses. citeturn0search5
The prescription patterns of sulphonylureas also vary based on patient demographics. A study analyzing real-world data from 91,230 patients aged 20 to 100 years found that glimepiride was the most commonly prescribed sulphonylurea (80.1%), followed by gliclazide (16.3%) and glibenclamide (3.6%). Among elderly patients (≥65 years), 25.0% exceeded the recommended glimepiride dosage of 1 mg/day, and 77.5% were prescribed glibenclamide, highlighting potential non-adherence to guidelines and the need for enhanced education on appropriate sulphonylurea usage to prevent hypoglycemia and diabetic complications. citeturn0search6
The evolving prescription patterns are influenced by several factors:
Clinical Guidelines: Japanese guidelines have shifted towards recommending newer antidiabetic agents with favorable safety and efficacy profiles, contributing to the reduced reliance on sulphonylureas.
Patient Safety: Concerns about hypoglycemia risk associated with sulphonylureas, especially in the elderly, have prompted healthcare providers to consider alternative therapies.
Industry Innovation: Pharmaceutical companies have focused on developing and marketing newer classes of antidiabetic drugs, such as DPP-4 inhibitors and SGLT2 inhibitors, which offer additional benefits beyond glucose control, including weight loss and cardiovascular protection.
In summary, while sulphonylureas continue to be a component of diabetes management in Japan, their role has diminished in favor of newer therapeutic options. This shift underscores the importance of aligning treatment strategies with current clinical guidelines and patient-specific factors to optimize outcomes in T2DM management.
Additionally, it's worth noting that similar trends have been observed in other pharmaceutical markets. For instance, the "100 Gigabit Fiber Optic Transceiver Market Type and requirement from industries" has also experienced shifts due to technological advancements and changing industry demands.
Get an In-Depth Research Analysis of the Japan Antidiabetic Sulphonylureas Market Size And Forecast [2025-2032]
Pfizer
AstraZeneca
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Pfizer
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Antidiabetic Sulphonylureas Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Antidiabetic Sulphonylureas Market
Sulfonylureas (First Generation)
Sulfonylureas (Second Generation)
Insulin Secretagogues
Potassium Channel Blockers
Oral Tablets
Oral Extended-Release Tablets
Hospitals
Clinics
Homecare Settings
Direct Sales
Retail Pharmacies
Online Pharmacies
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Antidiabetic Sulphonylureas Market Research Analysis
1. Introduction of the Japan Antidiabetic Sulphonylureas Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Antidiabetic Sulphonylureas Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Antidiabetic Sulphonylureas Market, By Type
6. Japan Antidiabetic Sulphonylureas Market, By Application
7. Japan Antidiabetic Sulphonylureas Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Antidiabetic Sulphonylureas Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/